Printer Friendly

CHRONIMED APPOINTED BY SANDOZ TO ADMINISTER PATIENT DRUG USE STUDY

 CHRONIMED APPOINTED BY SANDOZ TO ADMINISTER PATIENT DRUG USE STUDY
 MINNEAPOLIS, July 6 /PRNewswire/ -- Chronimed Inc. (NASDAQ: CHMD) has been appointed by Sandoz Pharmaceuticals to administer a clinical study at several transplant surgery centers throughout the country. The purpose of these clinical studies is to evaluate patient drug use compliance and to introduce a new delivery device for cyclosporine, the primary drug that prevents organ rejection.
 The company has also recently been appointed the endorsed provider of specialty pharmacy services to the Association of the Blue Cross/Blue Shield Organizations.
 Chronimed is a national distributor of pharmaceuticals, medical products and clinical nutrition products to patients with chronic health conditions. Chronimed also publishes educational materials for health professionals and for patients with chronic health conditions.
 -0- 7/6/92
 /CONTACT: Maurice R. Taylor of Chronimed, 612-541-0239/
 (CHMD) CO: Chronimed Inc.; Sandoz Pharmaceuticals ST: Minnesota IN: MTC SU:


KH -- MN009 -- 6796 07/06/92 18:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:155
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, MONDAY, JULY 6 /PRN/
Next Article:CYGNUS SHIPS ITS NICOTINE PATCH
Topics:


Related Articles
STUDY POINTS TO NEW HOPE FOR MIGRAINE SUFFERERS IN 50-YEAR-OLD DRUG
NAUSEA REDUCED IN MIGRAINE PATIENTS FOLLOWING ADMINISTRATION OF DHE-45, STUDY SHOWS
SANDOZ AND MARION MERRELL DOW ANNOUNCE CO-PROMOTION ARRANGEMENT
SANDOZ PHARMACEUTICALS CORPORATION AND CLINTRIALS RESEARCH INC. SIGN STRATEGIC ALLIANCE AGREEMENT
CLINTRIALS RESEARCH INC. AND SANDOZ PHARMACEUTICALS CORP. SIGN STRATEGIC ALLIANCE AGREEMENT
CHRONIMED AND THE PRUDENTIAL TO CO-DEVELOP COST-SAVINGS SPECIALTY PHARMACY PROGRAM
SANDOZ PHARMACEUTICALS CORP. AND VALUE HEALTH INC. SIGN LETTER OF INTENT: WILL WORK WITH TRANSPLANT COMMUNITY TO ENHANCE PATIENT CARE
ORION PHARMA GRANTS BROAD MARKETING RIGHTS OF PARKINSON'S DISEASE DRUG TO SANDOZ PHARMA LTD.
SANDOZ AND VALUE HEALTH, INC. COMPLETE TRANSPLANTATION AGREEMENT
Orphan Medical and Chronimed Terminate Distribution Agreement; Chronimed to Receive Compensation Valued at $2.5 Million

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters